Phase 2 Eczema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 12 or older who have atopic dermatitis (a type of eczema) that requires whole-body (systemic) treatment, not just creams or ointments
- People who have not used any whole-body (systemic) treatment for their eczema in the last 2 months, or who have never used that type of treatment before
- People who are able to use reliable contraception (birth control) for the duration of the study
Who may not be able to join:
- Women who are pregnant or breastfeeding, or women who could become pregnant and are not using an effective method of birth control
- People under 12 years of age
- People currently using other whole-body (systemic) eczema treatments, such as cyclosporin or biologic injections/infusions
- People who have used a whole-body (systemic) eczema treatment within the last 2 months
- People taking certain medications that affect specific liver enzymes known as CYP3A4 and CYP1A (confirm with trial site)
- People with serious conditions affecting other organs or body systems — particularly liver problems — though people with COPD (a lung condition) may still be considered
- People who have a known allergy or sensitivity to the study drug roflumilast or any of its ingredients
- People using a specific type of contraceptive pill containing gestodene and ethinylestradiol
- People who may have difficulty following the study requirements reliably (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Abeer Mohamed Elkholy, MD Dermatology, Faculty of medicine, Mansoura University
Phone: +201060291029
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary outcome of the study is the change in the SCORAD Index from baseline to the end of treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.